TY  - GEN
AU  - Avet-Loiseau,Hervé
AU  - Fonseca,Rafael
AU  - Siegel,David
AU  - Dimopoulos,Meletios A
AU  - Špička,Ivan
AU  - Masszi,Tamás
AU  - Hájek,Roman
AU  - Rosiñol,Laura
AU  - Goranova-Marinova,Vesselina
AU  - Mihaylov,Georgi
AU  - Maisnar,Vladimír
AU  - Mateos,Maria-Victoria
AU  - Wang,Michael
AU  - Niesvizky,Ruben
AU  - Oriol,Albert
AU  - Jakubowiak,Andrzej
AU  - Minarik,Jiri
AU  - Palumbo,Antonio
AU  - Bensinger,William
AU  - Kukreti,Vishal
AU  - Ben-Yehuda,Dina
AU  - Stewart,A Keith
AU  - Obreja,Mihaela
AU  - Moreau,Philippe
TI  - Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
SN  - 1528-0020
PY  - 2017///0804
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Dexamethasone
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Oligopeptides
KW  - Recurrence
KW  - Risk Factors
KW  - Survival Rate
KW  - Thalidomide
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1182/blood-2016-03-707596
ER  -